The nurse is caring for a client with swelling to the distal phalanges, first big toe, and 10/10 pain. Which medication below would be administered for this client's acute gout?
allopurinol
febuxostat
colchicine
physostigmine
The Correct Answer is C
A. Allopurinol is a xanthine oxidase inhibitor used for chronic gout management and prevention, not for acute attacks.
B. Febuxostat is also used for chronic management of gout and not effective for immediate relief of an acute attack.
C. Colchicine is indicated for the treatment of acute gout flares as it helps reduce inflammation and pain associated with gout attacks.
D. Physostigmine is an antidote for anticholinergic toxicity and has no role in treating gout.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is C
Explanation
A. Phenazopyridine does not typically cause an increase in blood pressure; this effect is not associated with the medication.
B. While gastrointestinal upset can occur, vomiting is not a primary or expected side effect of phenazopyridine.
C. A well-known side effect of phenazopyridine is orange or reddish urine, which results from the drug's dye properties.
D. Dizziness is not a common side effect; while it can occur, it is less specific to phenazopyridine compared to the characteristic orange urine.
Correct Answer is B
Explanation
A. Topical ointment has a slower onset as it must be absorbed through the skin before it can exert its effects.
B. Sublingual nitroglycerin provides rapid relief of angina symptoms because it is absorbed quickly into the bloodstream through the mucous membranes in the mouth, allowing for an immediate effect.
C. Transdermal patches release nitroglycerin slowly over time, leading to a delayed onset of action.
D. Sustained-release formulations are designed for prolonged effects rather than rapid onset, making them slower to take effect compared to sublingual administration.